GlassScriptPhysician profile
Frances B Abraham
NPI 1376005694
$5,300.24
in general payments reported to CMS, 2019-2025
49 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $462 · 2023: $1,458 · 2024: $1,426 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,428 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.35 |
| Education | $298.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $461.16 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $434.09 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $293.60 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $291.55 | 2023-2025 | Rybrevant, Carvykti, Talvey |
| Glaxosmithkline, LLC. | $261.58 | 2022-2025 | Ojjaara, Blenrep, Shingrix |
| Daiichi Sankyo INC. | $255.10 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Exelixis INC. | $246.27 | 2023-2025 | Cabometyx |
| Geron Corporation | $195.49 | 2025 | Rytelo |
| Eisai INC. | $191.11 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $177.61 | 2023-2025 | Orgovyx |
| Lilly USA, LLC | $157.17 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $156.73 | 2023-2025 | |
| Amgen INC. | $140.05 | 2021-2023 | Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $134.57 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Rigel Pharmaceuticals, INC. | $134.50 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $130.05 | 2024-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $120.39 | 2022-2024 | Onivyde, Somatuline Depot, Tazverik |
| Abbvie INC. | $116.42 | 2023-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $114.81 | 2023-2025 | Ultomiris |
| Seagen INC. | $93.40 | 2022-2023 | Tukysa, Padcev, Adcetris |
| Celgene Corporation | $80.94 | 2022-2025 | Pomalyst, Opdualag, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $80.32 | 2022-2025 | Libtayo |
| Array Biopharma INC | $76.87 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $73.75 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $72.77 | 2022-2024 | Monoferric, Cosela |
| Adc Therapeutics America, INC. | $67.94 | 2023-2024 | |
| Beone Medicines USA, INC. | $66.91 | 2025 | Tevimbra, Brukinsa |
| Tolmar, INC. | $56.83 | 2024-2025 | Eligard, Jatenzo, Rubraca |
| Springworks Therapeutics, INC. | $53.95 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $48.07 | 2023 | Besremi |
| Genentech USA, INC. | $48.07 | 2023-2025 | Tecentriq, Itovebi |
| Beigene USA, INC. | $45.84 | 2023-2024 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $39.46 | 2025 | Vyloy, Xtandi |
| Aveo Pharmaceuticals, INC. | $36.14 | 2022-2024 | |
| Morphosys, US INC. | $36.00 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $34.12 | 2023-2024 | Xermelo |
| Astrazeneca Pharmaceuticals LP | $33.29 | 2023-2025 | Lynparza, Imfinzi |
| Myovant Sciences INC. | $32.86 | 2022 | |
| Sobi, INC | $29.09 | 2023-2025 | |
| Genmab U.S., INC. | $28.67 | 2024-2025 | Epkinly |
| Myriad Genetic Laboratories, INC. | $21.52 | 2023 | Bracanalysis Cdx |
| Syndax Pharmaceuticals, INC. | $20.78 | 2025 | Revuforj |
| Jazz Pharmaceuticals INC. | $18.71 | 2023 | |
| G1 Therapeutics, INC. | $17.95 | 2022 | |
| Gilead Sciences, INC. | $17.07 | 2024 | Trodelvy |
| Novocure INC. | $15.01 | 2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $14.91 | 2022 | |
| Pharmaand Gmbh | $13.79 | 2025 | Rubraca |
| Foundation Medicine, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.